The structured gene field (known_genes) and the structured inheritance field (inheritance_patterns) are empty in this packet, so this summary names no specific genes and states no inheritance pattern, and this reflects what the packet certifies rather than a finding that none exist. GeneReviews describes the mechanism as decreased activity of the BCKD complex, which impairs the second step in breakdown of the branched-chain amino acids leucine, isoleucine, and valine. It states that the severity of the metabolic phenotype is determined by the amount of residual BCKD enzyme activity relative to dietary branched-chain amino acid intake and to the demands for their oxidation during fasting, illness, or other catabolic stress. GeneReviews also reports that, although some relationships between genotype and biochemical phenotype are established (classic versus intermediate), clinical and functional outcomes such as full-scale IQ, psychiatric illness, and executive dysfunction cannot be predicted from genotype, and that individuals with the same genotype may differ considerably in cerebral response to metabolic crisis. GeneReviews also reports a founder variant in certain Mennonite populations, with disease incidence of approximately one in 380 live births there.

The packet lists newborn screening for MSUD as a CORE category condition. GeneReviews describes two presentation scenarios. In the first, an abnormal newborn screen, screening is primarily based on ratios of (leucine plus isoleucine) to alanine and phenylalanine on dried blood spots; a positive screen is followed by quantitative plasma amino acid and alloisoleucine analyses, and GeneReviews states that treatment and diagnostic testing are started concurrently if either is abnormal. Because mass spectrometry cannot distinguish leucine-isoleucine from hydroxyproline, neonates with isolated hydroxyprolinemia screen positive, a false positive that confirmatory amino acid analysis resolves. In the second scenario, a symptomatic individual presents with atypical findings or untreated infantile-onset disease. Supportive laboratory findings listed include elevated plasma branched-chain amino acids and alloisoleucine, urinary branched-chain alpha-ketoacids, ketonuria, and absence of hypoglycemia and hyperammonemia. GeneReviews states that diagnosis in a proband with suggestive biochemical findings is established by biallelic pathogenic or likely pathogenic variants in one of the associated genes or, in limited instances, by significantly reduced BCKD activity in cultured fibroblasts, leukocytes, or liver tissue. It adds that molecular testing is increasingly the preferred confirmatory test. The differential diagnosis in GeneReviews includes birth asphyxia, hypoglycemia, kernicterus, meningitis, encephalitis, urea cycle defects, nonketotic hyperglycinemia, and certain organic acidemias; the sweet odor of cerumen is described as distinctive for MSUD.

The packet contains no FDA-approved treatment records. Three orphan drug designations are listed, each with status DESIGNATED, which denotes a designation and not marketing approval: a modified leucine decarboxylase enzyme (sponsor Codexis, Inc.), an AAV9 vector expressing BCKDH subunit genes (sponsor Clinic for Special Children), and sodium phenylbutyrate (sponsor Acer Therapeutics, Inc.). GeneReviews describes management as dietary and multidisciplinary. It states that metabolic treatment is initiated immediately when MSUD is suspected on the basis of elevated leucine, isoleucine, valine, or alloisoleucine, and that care involves oversight and expertise from a specialized metabolic center, with a metabolic physician or biochemical geneticist and a specialist metabolic dietitian. The main treatment principles are age-appropriate tolerance of leucine, isoleucine, and valine, with stable plasma branched-chain amino acid concentrations and ratios, while preventing deficiencies of essential amino acids, fatty acids, and micronutrients. Routine daily treatment is described as leucine restriction matched to individual tolerance, with branched-chain amino acid-free formula, natural protein, and isoleucine and valine supplementation. Other described evaluations include developmental assessment and neurology, psychiatry, psychology, and therapy input as needed. GeneReviews describes surveillance as periodic full amino acid profiles at a frequency varying with age and metabolic stability, periodic visits with a metabolic specialist, and attention to developmental milestones. These are descriptions of the GeneReviews content and not individualized guidance.

The packet carries no certified natural-history field or survival statistics, so no life expectancy or survival figures are given. GeneReviews states that long-term outcomes are largely related to the timing and quality of metabolic control, and that outcomes vary among individuals with the same genotype. It describes that untreated classic disease can progress within days of birth to encephalopathy, coma, and central respiratory failure, and that episodes of metabolic intoxication can be fatal even in individuals with relatively high residual enzyme activity. The packet's definition similarly states that, if untreated, the condition may lead to seizures, coma, and death. GeneReviews further reports that the frequency of amino acid testing correlates with metabolic control and with long-term measures of intelligence.

The packet lists three ClinicalTrials.gov records, reported here with the status and dates as recorded and not as a current enrollment confirmation. NCT03655223, "Early Check: Expanded Screening in Newborns" (sponsor RTI International), has status ACTIVE_NOT_RECRUITING, with a start date of 2018-10-15 and a completion date of 2026-12-31. NCT06664840, "MyRareDiet A Novel Diet Tracking Tool" (phase NA, sponsor Oregon Health and Science University), has status NOT_YET_RECRUITING, with a recorded start of 2024-11-15 and completion of 2025-12-31. NCT04602325, "Systemic Biomarkers of Brain Injury From Hyperammonemia" (sponsor Children's National Research Institute), has status RECRUITING, with dates of 2020-07-09 to 2027-05-01. Its literature digest classifies 98 publications, most commonly case reports or case series. The packet lists the patient organization flok Health (https://flok.org).